Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managers

Besides INFI, mega fund managers also accumulated the following small-cap biotech stocks in Q4/2012 (see Table below):

• Sarepta Therapeutics (SRPT), that develops RNA-based therapeutics for the treatment of genetic, infectious and other diseases, in which mega funds together added a net 2.62 million shares in Q4 to their 2.89 million share prior quarter position in the company. In our review earlier of guru fund picks in small-cap biotech stocks, SRPT was also a top buy among guru funds in Q4.
• Mannkind Corp. (MNKD), a developer of treatments for cancer, diabetes, inflammatory and autoimmune diseases, with its lead product candidates the AFREZZA dry powder insulin formulation and its proprietary light, discrete and easy-to-use AFREZZA inhaler through which the powder is inhaled deep into the lungs, in which mega funds together added a net 4.51 million shares in Q4 to their 23.46 million share prior quarter position in the company. MNKD was also a top buy among guru funds in Q4.
• Galena Biopharma Inc. (GALE), that is a biotech company engaged in the development of innovative targeted, oncology treatments, in which mega funds together added a net 0.85 million shares in Q4 to their 3.31 million share prior quarter position in the company.

http://seekingalpha.com/article/1410411-top-small-cap-biotech-stocks-being-accumulated-by-large-fund-managers?source=google_news